Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneus Ltd. ( (AU:CMB) ) just unveiled an update.
Cambium Bio Limited has made significant progress in its Phase 3 trials for Elate Ocular®, a treatment for dry eye disease, with ethics approvals obtained in both Australia and the United States. The company is preparing for patient dosing after satisfying FDA requirements and has secured additional funding to support its clinical operations. The financial report highlights a disciplined approach to managing costs, with a focus on research and development, while maintaining a conservative cash balance to achieve near-term milestones.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company focusing on developing innovative biologics for ophthalmology and tissue repair applications.
Average Trading Volume: 10,284
Technical Sentiment Signal: Sell
Current Market Cap: A$5.85M
For an in-depth examination of CMB stock, go to TipRanks’ Overview page.